EVABOSMIG
UNII QM3EL2C844
Substance Identification & Data
This profile provides standardized clinical and technical data for Evabosmig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) QM3EL2C844.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3061142-96-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
QM3EL2C844
3061142-96-6
N/A
Detailed Substance Profile
Preferred Name
EVABOSMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13895
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Evabosmig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Evabosmig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Evabosmig
Common Names & Synonyms
H-gamma4 heavy chain anti-SOST humanized hole (H) (1-442) [VH (Homo sapiens IGHV1-18*01 (84.4%) -(IGHD) -IGHJ5*01 (90.9%) L123>T (110), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 14-G4v33 CH3 S22, A24, V86 (hole), 10-G4v83 CH3 R115, F116 (CH1 (116-213), hinge 1-12 S10>P (223) (214-225), CH2 L92 (304) (226-335), CH3 T22>S (361), L24>A (363), Y86>V (402), H115>R (430), Y116>F (431) (336-440), CHS (441-442)) (116-442)], (129-219')-disulfide with L-kappa light chain anti-SOST humanized (L') (1'-219') [V-KAPPA (Homo sapiens IGKV1-39*01 (79.0%) -IGKJ4*01 (100%), CDR-IMGT [11.3.9] (27'-37'.55'-57'.94'-102')) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'), V101 (196')) (113'-219')]; H-gamma4 heavy chain anti-DKK1 humanized knob (H'') (1''-447'') [VH (Homo sapiens IGHV3-30*01 (91.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26''-33''.51''-58''.97''-109'')) (1''-120'') -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 12-G4v17 CH1 S10, 14-G4v32 CH3 W22 (knob), 17-G4v57-4 CH1 S10, C84(CH1 C10>S (134), V84>C (176) (121''-218''), hinge 1-12 S10>P (228'') (219''-230''), CH2 L92 (309'') (231''-340''), CH3 T22>W (366) (341''-445''), CHS (446''-447'')) (121''-447'')], (176''-160''')-disulfide with L-kappa light chain anti-DKK1 humanized (L''') (1'''-214''') [V-KAPPA (Homo sapiens IGKV1D-43*01 (88.3%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'''-32'''.50'''-52'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (99.1%) Km3 A45.1, V101, 17-KCv57-4 C79, S126 (C-KAPPA A45.1 (153'''), V101 (191'''), Q79>C (160'''), C126>S (214''')) (108'''-214''')]; dimer (221-226'':224-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
Immunoglobulin G4 [134-serine,176-cysteine,228-proline,366-tryptophan], bispecific, anti-(human dickkopf 1) (human-Mus musculus monoclonal 11H10 γ4-chain), (176→160′′′)-disulfide with [160′′′-cysteine,214′′′-serine] human-Mus musculus monoclonal 11H10 κ-chain, (226→221′),(229→224′)-bis(disulfide) with immunoglobulin G4 [223′-proline,361′-serine,363′-alanine,402′-valine,430′-arginine,431′-phenylalanine] anti-(human sclerostin) (human-Mus musculus monoclonal 93B1B7 .gamma.4-chain) (129′→219′′)-disulfide with human-Mus musculus monoclonal 93B1B7 κ-chain
evabosmig [INN]
immunoglobulin (H-gamma4_L-kappa) (H-gamma4_L-kappa), anti-[Homo sapiens SOST (sclerostin)] and anti-[Homo sapiens DKK1 (dickkopf Wnt signaling pathway inhibitor 1, SK, DKK-1)], humanized monoclonal antibody, bispecific, bivalent (evabosmig)
